Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Phase II Multiple Dose Safety, Pharmacokinetic and Pharmacodynamics Study of SEL-212 Followed by Open Label Administration of SEL-037 in Subjects With Symptomatic Gout and Elevated Blood Uric Acid

NCT02959918 is registered in ClinicalTrials.gov with Selecta Biosciences, Inc. as lead sponsor.

NCT NCT02959918
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02959918 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Phase II Multiple Dose Safety, Pharmacokinetic and Pharmacodynamics Study of SEL-212 Followed by Open Label Administration of SEL-037 in Subjects With Symptomatic Gout and Elevated Blood Uric Acid
Lead sponsor
Selecta Biosciences, Inc.
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2016
Completion date
January 31, 2019
Enrollment
152 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

gout chronic, hyperuricemia